Paul G. Allen Frontiers Group [to 16 Nov 2019]
No new digest content identified.


BMGF – Gates Foundation [to 16 Nov 2019]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 16 Nov 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 16 Nov 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 16 Nov 2019]
12 Nov 2019
Lassa Fever – an emerging disease we should look out for
By Erich Tauber
…Themis just announced the initiation of a Phase 1 clinical trial in healthy adult volunteers to investigate the safety, tolerability and immunogenicity of the MV-LASV vaccine candidate. MV-LASV was developed using a proprietary measles vector platform for prophylaxis of Lassa virus infection. What makes Themis’ technology unique is that the delivery vehicle that is used is the measles vaccine vector, which historically has a proven track-record of safety and potency as evidenced by the billions of people who have already been vaccinated world-wide. Themis applies this knowledge to develop innovative vaccine candidates including the one against Lassa fever…


Clinton Health Access Initiative, Inc. (CHAI) [to 16 Nov 2019]
News & Press Releases
Clinton Health Access Initiative releases 2018 Annual Report
Published November 13th, 2019
…Highlights of this year’s report include:
– A breakthrough pricing agreement to significantly lower the cost of state-of-the-art diagnostic testing for HIV, hepatitis, and cervical cancer in low- and middle-income countries at a price of US$12 per patient sample.
– Expanding our integrated approach to maternal, newborn, and reproductive health to countries including Zambia, Uganda, and South Africa.
– A 58 percent reduction, on average, on the price of handheld pulse oximeters- simple, life-saving tools that can help to quickly diagnose severe pneumonia…


EDCTP [to 16 Nov 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
12 November 2019
Novartis will support five Career Development Fellowships on maternal and child health
Novartis and EDCTP are pleased to highlight the sponsorship agreement to support research capacity development in sub-Saharan Africa. Within the framework of EDCTP’s 2019 Career Development Fellowships, Novartis will jointly fund fellows that aim to conduct research in the field…


Emory Vaccine Center [to 16 Nov 2019]
No new digest content identified.


European Medicines Agency [to 16 Nov 2019]
News & Press Releases
Press release
First vaccine to protect against Ebola (updated)
CHMP, Last updated: 14/11/2019
[See Milestones above for detail]


European Vaccine Initiative [to 16 Nov 2019]
No new digest content identified.


FDA [to 16 Nov 2019]
Press Announcements
No new digest content identified.


Fondation Merieux [to 16 Nov 2019]
News, Events
December 3 – 4, 2019 – Geneva (Switzerland)
Mérieux Foundation co-organized event
6th GTFCC Working Group on Oral Cholera Vaccine

20 – 22 Jan 2020
Mérieux Foundation co-organized event
Dengue pre-vaccination screening strategies workshop
Les Pensières Center for Global Health, Veyrier-du-Lac (France)


Gavi [to 16 Nov 2019]
Latest news
Pakistan becomes first country to introduce new typhoid vaccine into routine immunisation program  
15 November 2019
Gavi-supported introduction of new and improved typhoid conjugate vaccine to offer protection against increasingly drug-resistant disease.

New partnership launched to increase uptake of life-saving vaccines in Rwanda  
12 November 2019
Gavi, the Government of Rwanda and Girl Effect launch a 13-month partnership that will use innovative behaviour change communications to address gender related barriers to vaccine uptake.

Gavi welcomes European Commission approval of first Ebola vaccine  
12 November 2019
The European Commission has granted conditional marketing authorisation to the Ervebo Ebola vaccine in European Union member states.


GHIT Fund [to 16 Nov 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 16 Nov 2019]
News & Stories
Global Fund Board Steps Up Efforts to Expand Impact Against HIV, TB and Malaria
15 November 2019
… At the Board’s 42nd meeting, coming one month after a successful Sixth Replenishment that secured pledges of over US$14 billion for 2020-2022, Board members expressed appreciation for the collective efforts that led to such a strong mobilization of resources, calling it a compelling affirmation of commitment toward achieving greater social justice all over the world.
… The Board approved a decision that translates pledges made at the Replenishment Conference into funding for country allocations for the 2020-2022 period, as well as certain catalytic investments that can further enhance impact in priority areas. The Global Fund plans to finalize the allocation and inform countries in December 2019.
The Board also approved a decision to advance the development of, an innovative online tool that gives in-country procurement teams the power to search, compare and purchase quality-assured products used by health programs. The Board’s decision allows to be made available for non-Global Fund-financed orders by governments and nongovernment development organizations on a variety of products…

Donor Pledges and Contributions
12 November 2019
The Pledges and Contributions Report, a spreadsheet with a complete view of each donor’s pledges and contributions, is fully updated with Sixth Replenishment pledges and the dozens of new donors: Pledges and Contributions Report Excel | PDF

Sourcing & Management of Health Products
Opportunity for Evaluation of Diagnostic Products
11 November 2019
The Global Fund and Unitaid are inviting manufacturers of diagnostic products to submit an Expression of Interest to have their products evaluated by the Expert Review Panel for Diagnostics (EPRD).


Hilleman Laboratories [to 16 Nov 2019]
No new digest content identified.


Human Vaccines Project [to 16 Nov 2019]
Press Releases
No new digest content identified.


IAVI [to 16 Nov 2019]
Press Releases
November 12, 2019
Award from U.S. Department of Defense to Advance Marburg Virus Vaccine Candidate Development
Marburg virus has epidemic potential and is a high-priority agent that poses a national security threat
NEW YORK — NOVEMBER 12, 2019 — IAVI announced today the award of $35.7M from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to develop a recombinant vesicular stomatitis virus (VSV) vector Marburg virus vaccine candidate. This award builds on IAVI’s expertise in VSV vector technology that it has developed through its own VSV HIV vaccine candidate and VSV Lassa fever vaccine candidate, which are in preclinical development. The Marburg virus vaccine candidate, licensed by IAVI from the Public Health Agency of Canada, demonstrated strong protection from the deadly disease in non-human primate studies…



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.



No new digest content identified.


IFRC [to 16 Nov 2019]
Selected Press Releases, Announcements
No new digest content identified.


IVAC [to 16 Nov 2019]
Report card on preventing global pneumonia and diarrhea deaths in children finds stalled progress
November 2019
The 10th annual Pneumonia & Diarrhea Progress Report Card from the International Vaccine Access Center highlights increases in immunization coverage but universal failure to meet targets in countries with the greatest burden of disease.


IVI [to 16 Nov 2019]
Selected IVI News & Announcements
IVI to Accelerate Efforts in iNTS Vaccine Development
:: An award from the Wellcome Trust’s Affordable Innovations for Global Health Flagship will support IVI’s development and selection of potential vaccine candidates
:: There is currently no vaccine available to protect against invasive non-typhoidal salmonella (iNTS)
November 13, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI) has received a $3.33 million grant from the Wellcome Trust to identify and select promising vaccine candidates against invasive non-typhoidal salmonella (iNTS), an enteric disease that disproportionately affects the world’s poorest populations.
iNTS may cause up to 680,000 deaths every year, primarily in resource-poor settings in sub-Saharan Africa. Treatment is difficult and complicated by emerging antibiotic resistance, meaning therapeutic options are limited and expensive, if not inaccessible. With no vaccine currently available to prevent infection by these bacteria, IVI made a targeted investment in non-typhoidal Salmonella (NTS) vaccine development, anticipating a potential combination with IVI’s typhoid conjugate vaccine (TCV) that is now entering Phase III trials in Nepal, the Philippines and Indonesia. Going forward, this award from the Wellcome Trust will leverage that initial investment and help IVI accelerate vaccine development timelines and prepare for trials in humans.
“Developing a vaccine against invasive non-typhoidal Salmonella is a logical addition to our vaccine portfolio,” says Dr. Jerome Kim, Director General of IVI. “IVI’s efforts to reduce the burden of Salmonella Typhi date to the early 2000s when we first launched DOMI in Asia, and data collected in the past decade from Africa suggests that NTS disease is highly endemic in many African settings.”…


JEE Alliance [to 16 Nov 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 16 Nov 2019]
Latest [Selected Announcements]
Statements and Press Releases
No new digest content identified.


National Vaccine Program Office – U.S. HHS [to 16 Nov 2019]
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)


NIH [to 16 Nov 2019]
Selected News Releases
Thursday, November 14, 2019
NIH, NIST researchers use artificial intelligence for quality control of stem cell-derived tissues
Technique key to scale up manufacturing of therapies from induced pluripotent stem cells.


PATH [to 16 Nov 2019]
Selected Announcements
PATH and partners receive award for development of world’s first malaria vaccine
November 13, 2019 by PATH
Pilot introduction of RTS,S/AS01 has now started in selected areas of three African countries
November 13, 2019, WASHINGTON, D.C. – PATH and partners today received the Global Health Technologies Coalition (GHTC) 2019 Innovating for Impact Partnership Award, for the development and phased introduction of RTS,S/AS01, the world’s first malaria vaccine. The vaccine was introduced by ministries of health in areas of Ghana, Kenya, and Malawi in 2019 as part of a pilot program coordinated by the World Health Organization (WHO).

The award was accepted by the director of PATH’s Malaria Vaccine Initiative, Dr. Ashley Birkett and Dr. Opokua Ofori-Anyinam, Director of Clinical Development at GSK Vaccines, at a recognition dinner at the Newseum in Washington, DC before an audience of US government officials, policymakers, media, and leaders in the global health and medical research communities. Drs. Birkett and Ofori-Anyinam accepted the award on behalf of all partners, including the Walter Reed Army Institute of Research and WHO.

The award is presented annually to an innovative product development partnership that has advanced a high-impact, game-changing global health technology. Honorees are chosen by a committee of global health experts.

“On behalf of PATH and all our partners in the development of RTS,S from around the world, we are honored to receive this award. We have worked with GSK Vaccines for almost 20 years, and we’re proud to have contributed to bringing this first malaria vaccine to children,” said Birkett. “This vaccine reflects PATH’s commitment to reducing the deadly toll of malaria among the most vulnerable–young children—even as we work towards the ultimate goal of eradicating malaria completely. We look forward to continuing to advance malaria vaccine development in support of that goal.”…


Sabin Vaccine Institute [to 16 Nov 2019]
Statements and Press Releases
No new digest content identified.


UNAIDS [to 16 Nov 2019]
Selected Press Releases/Reports/Statements
14 November 2019
Pace of decline in new adult HIV infections remains short of ambition
The co-conveners of the Global HIV Prevention Coalition, UNAIDS and the United Nations Population Fund, have launched a new report on progress made in reducing new HIV infections across 28 countries that have been particularly affected by HIV. The report was launched at the High-Level Meeting of the Global HIV Prevention Coalition, held on 12 November on the sidelines of the Nairobi Summit on ICPD25.
Together, the 28 countries account for 75% of all new HIV infections globally—1.2 million of the 1.7 million new HIV infections among adults in 2018. The report, Implementation of the HIV prevention 2020 road map, shows that among the coalition countries new HIV infections among adults declined on average by 17% since 2010, slightly higher than the global decline of 13%, but far short of the 60% decline needed in 2018 to meet global HIV prevention targets…

13 November 2019
UNAIDS Executive Director holds first face-to-face meeting with key donors

12 November 2019
Statement of commitment to step up action towards ending AIDS, eliminate social injustice and reach the women and girls being left behind
This year marks the 25th anniversary of the International Conference on Population and Development (ICPD),  where 179 governments adopted a landmark Programme of Action. The Programme of Action unequivocally affirmed reproductive rights as human rights, fundamental to the empowerment of women and girls and to achieving gender equality and sustainable development more broadly.
From 12 to 14 November, the governments of Kenya and Denmark, together with the United Nations Population Fund (UNFPA), are co-convening the Nairobi Summit to mobilize the political will and financial commitments needed to finally and fully implement the Programme of Action…

12 November 2019
The power of transgender visibility in Jamaica

12 November 2019
HIV-related discrimination far too high


UNICEF [to 16 Nov 2019]
Selected Statements, Press Releases, Reports
Press release 11/11/2019
One child dies of pneumonia every 39 seconds, agencies warn
Pneumonia – a preventable disease – kills more children than any other infection


Vaccination Acceptance Research Network (VARN) [to 16 Nov 2019]
No new digest content identified.


Vaccine Confidence Project [to 16 Nov 2019]
VACCINES & FAKE NEWS: Analysing measles outbreaks 2019
Posted on 10 Nov, 2019
By  Lola García-Ajofrín
Even though it is a vaccine-preventable disease, measles kills over 100,000 people every year. Worldwide cases tripled in the first three months of 2019. The causes of these outbreaks are diverse: from health infrastructure to civil


Vaccine Education Center – Children’s Hospital of Philadelphia [to 16 Nov 2019]
No new digest content identified.


Wellcome Trust [to 16 Nov 2019]
Opinion | 14 November 2019
Landmark moment in the fight against Ebola: what have we learnt?
by Charlie Weller

Opinion | 13 November 2019
With better global data we can outsmart drug-resistant infections
by Gemma Buckland Merrett
The impact of drug-resistant infections is much higher than previously thought, as shown in a new report from the Centers for Disease Control.

Opinion | 12 November 2019
Does the way Wellcome makes funding decisions support the right research?
by Jonathan Best


The Wistar Institute [to 16 Nov 2019]
Press Release Nov. 14, 2019
International Collaboration for Scientific Training Launched Between The Wistar Institute and Leiden University Medical Center in the Netherlands
Wistar and Leiden University Medical Center (LUMC) formalized a memorandum of understanding between the two institutions to explore a postdoctoral training exchange program in immunology, cancer research and vaccine biology.


World Organisation for Animal Health (OIE) [to 16 Nov 2019]
A new OIE Sub Regional Representation for Middle East opens in United Arab Emirates
On the occasion of the 15th Conference of the OIE Regional Commission for the Middle East, the OIE officially opens its Sub Regional Representation for Middle East in United Arab Emirates. This new office will strengthen the region’s cooperation with the OIE and among its Members thereby addressing their main concerns, such as the control of transboundary animal diseases, including zoonoses, and animal welfare in particular in the context of trade purposes.





ARM [Alliance for Regenerative Medicine] [to 16 Nov 2019]
No new digest content identified.


BIO [to 16 Nov 2019]
No new digest content identified.


DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Nov 2019]
WHO Director General addressed the delegates of the DCVMN Annual General Meeting 2019
Rio de Janeiro, 22nd October 2019 – On the occasion of the 20th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN), held on Brazil, WHO Director General, Dr. Tedros Ghebreyesus, addressed the delegates by video. He highlighted that “vaccines are one of the most accessible and cost-effective tools in the history of healthcare. Smallpox has been eradicated, polio is on the brink, and millions of lives have been saved from measles, meningitis and other diseases thanks to vaccines.” However, many children are missing out vaccination and preventable diseases are still a major cause of illness and death. Low and middleincome countries have been slower in adopting vaccines than high-income countries, and one of the barriers has been the lack of resources and regulatory systems.

The DCVMN members have made a vital contribution to increasing the quality, availability and affordability of vaccines. There are now over 70 WHO prequalified vaccines from DCVMN members, including rotavirus, yellow fever, cholera and more, he mentioned.

He added that “our next challenge is to use collaborative ways to translate these vaccines availability into national licences for use in countries. Low resources, heavy workload and untrained staff in many countries mean that vaccines take longer to reach children.” He thanked DCVMN and all its Partners, Gavi, UNICEF, BMGF and others, for their support and commitment. “Together we can overcome the barriers we face, and ensure that all children enjoy the lifesaving power of vaccines” he concluded.


IFPMA [to 16 Nov 2019]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 16 Nov 2019]
Selected Press Releases, Statements
Website not responding at inquiry.